KR20130119951A - PI3K/mTOR의 억제제로서의 벤즈옥사제핀 및 그의 이용 방법 및 제법 - Google Patents
PI3K/mTOR의 억제제로서의 벤즈옥사제핀 및 그의 이용 방법 및 제법 Download PDFInfo
- Publication number
- KR20130119951A KR20130119951A KR1020137016292A KR20137016292A KR20130119951A KR 20130119951 A KR20130119951 A KR 20130119951A KR 1020137016292 A KR1020137016292 A KR 1020137016292A KR 20137016292 A KR20137016292 A KR 20137016292A KR 20130119951 A KR20130119951 A KR 20130119951A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- dihydro
- alkyl
- benzimidazol
- pyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41716510P | 2010-11-24 | 2010-11-24 | |
| US61/417,165 | 2010-11-24 | ||
| PCT/US2011/062025 WO2012071501A1 (fr) | 2010-11-24 | 2011-11-23 | Benzoxazépines en tant qu'inhibiteurs de pi3k/mtor et procédés de leurs utilisation et fabrication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130119951A true KR20130119951A (ko) | 2013-11-01 |
Family
ID=45099217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137016292A KR20130119951A (ko) | 2010-11-24 | 2011-11-23 | PI3K/mTOR의 억제제로서의 벤즈옥사제핀 및 그의 이용 방법 및 제법 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140073628A1 (fr) |
| EP (1) | EP2643315A1 (fr) |
| JP (1) | JP2013544826A (fr) |
| KR (1) | KR20130119951A (fr) |
| CN (1) | CN103384667A (fr) |
| AU (1) | AU2011332849A1 (fr) |
| BR (1) | BR112013012950A2 (fr) |
| CA (1) | CA2818898A1 (fr) |
| EA (1) | EA201390757A1 (fr) |
| MX (1) | MX2013005821A (fr) |
| WO (1) | WO2012071501A1 (fr) |
| ZA (1) | ZA201303855B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2616442B8 (fr) | 2010-09-14 | 2018-10-17 | Exelixis, Inc. | Inhibiteurs de pi3k-delta et leurs procédés d'utilisation et fabrication |
| CN104302294A (zh) | 2011-11-01 | 2015-01-21 | 埃克塞利希斯股份有限公司 | 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3-激酶抑制剂的n-(3-{[(3-{[2-氯-5-(甲氧基)苯基]氨基}喹喔啉-2-基)氨基]磺酰基}苯基)-2-甲基丙氨酰胺 |
| CN102786512A (zh) * | 2012-05-31 | 2012-11-21 | 中国人民解放军军事医学科学院毒物药物研究所 | N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用 |
| WO2019075386A1 (fr) * | 2017-10-13 | 2019-04-18 | The Regents Of The University Of California | Modulateurs de mtorc1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090233926A1 (en) * | 2006-09-14 | 2009-09-17 | Astrazeneca | 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| EP2432779A1 (fr) * | 2009-05-22 | 2012-03-28 | Exelixis, Inc. | Inhibiteurs de pi3k/mtor à base de benzoxazépines pour lutter contre les maladies prolifératives |
| WO2010135568A1 (fr) * | 2009-05-22 | 2010-11-25 | Exelixis, Inc. | Benzoxazépines en tant qu'inhibiteurs de mtor et leur utilisation pour traiter le cancer |
-
2011
- 2011-11-23 BR BR112013012950A patent/BR112013012950A2/pt not_active IP Right Cessation
- 2011-11-23 EA EA201390757A patent/EA201390757A1/ru unknown
- 2011-11-23 EP EP11791722.9A patent/EP2643315A1/fr not_active Withdrawn
- 2011-11-23 JP JP2013541040A patent/JP2013544826A/ja active Pending
- 2011-11-23 CA CA2818898A patent/CA2818898A1/fr not_active Abandoned
- 2011-11-23 MX MX2013005821A patent/MX2013005821A/es not_active Application Discontinuation
- 2011-11-23 US US13/988,948 patent/US20140073628A1/en not_active Abandoned
- 2011-11-23 CN CN2011800658557A patent/CN103384667A/zh active Pending
- 2011-11-23 WO PCT/US2011/062025 patent/WO2012071501A1/fr active Application Filing
- 2011-11-23 KR KR1020137016292A patent/KR20130119951A/ko not_active Application Discontinuation
- 2011-11-23 AU AU2011332849A patent/AU2011332849A1/en not_active Abandoned
-
2013
- 2013-05-24 ZA ZA2013/03855A patent/ZA201303855B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013005821A (es) | 2013-08-27 |
| CN103384667A (zh) | 2013-11-06 |
| CA2818898A1 (fr) | 2012-05-31 |
| JP2013544826A (ja) | 2013-12-19 |
| AU2011332849A1 (en) | 2013-06-20 |
| WO2012071501A1 (fr) | 2012-05-31 |
| ZA201303855B (en) | 2014-01-29 |
| EP2643315A1 (fr) | 2013-10-02 |
| US20140073628A1 (en) | 2014-03-13 |
| EA201390757A1 (ru) | 2013-11-29 |
| BR112013012950A2 (pt) | 2017-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20130119950A (ko) | PI3K/mTOR의 저해물질들로써 벤족사제핀 및 이의 사용 및 제조 방법들 | |
| US20140080810A1 (en) | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | |
| US20140066431A1 (en) | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | |
| WO2012071509A2 (fr) | Benzoxazépines utilisées comme inhibiteurs de p13k/mtor et procédés d'utilisation et de fabrication | |
| US8648066B2 (en) | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | |
| JP2021100960A (ja) | 肺がん、膵臓がん、または大腸がんを治療するためのＫＲＡＳ Ｇ１２Ｃ阻害剤としての、ベンズイソチアゾール、イソチアゾロ［３，４−ｂ］ピリジン、キナゾリン、フタラジン、ピリド［２，３−ｄ］ピリダジンおよびピリド［２，３−ｄ］ピリミジン誘導体 | |
| KR20140000706A (ko) | PI3K/mTOR의 억제제로서의 벤즈옥사제핀 및 그의 이용 방법 및 제법 | |
| KR20180074788A (ko) | 암의 치료에 유용한 디하이드로이미다조피라지논 유도체 | |
| WO2017080980A1 (fr) | Dérivés de dihydropyrrolopyrazinone utiles dans le traitement du cancer | |
| US20230183197A1 (en) | Inhibitors of mlh1 and/or pms2 for cancer treatment | |
| KR20130119951A (ko) | PI3K/mTOR의 억제제로서의 벤즈옥사제핀 및 그의 이용 방법 및 제법 | |
| KR20140004661A (ko) | mTOR의 억제제로서의 벤즈옥사제핀 및 그의 이용 방법 및 제법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |